Martek Biosciences Corp

Martek Biosciences — Investor Day (March 2010)

39 slides from Martek Biosciences's investor day presentation, Mar 5, 2010

  1. Slide 1: Martek Biosciences Investor Day

    Martek Biosciences Investor Day March 5, 2010 New York, NY

  2. Slide 2: Kyle Stults, Director of Investor Relations

    Kyle Stults Director of Investor Relations 2

  3. Slide 3: Forward Looking Statements

    Forward Looking Statements 3 Sections of this presentation contain forward-looking statements concerning, among other things, expectations regarding future revenue growth, product introductions, production expansion, capital expenditures and gross margins. These statements are based upon numerous as

  4. Slide 4: Agenda

    Agenda Speaker Topic Steve Dubin, CEO Welcome and Opening Remarks Peter Nitze, COO Research Engine and Pipeline Review Question and Answer Session Philip New, CEO, BP Biofuels Sugars-to-Biodiesel Overview Question and Answer Session David Abramson, President Strategic Value of Amerifit and Branded P

  5. Slide 5: Steve Dubin, Chief Executive Officer

    Steve Dubin Chief Executive Officer 5

  6. Slide 6: Martek's Roots

    Martek’s Roots 6 Microbial biotechnology Significant expertise in the development and production of high value products from microbial sources Expanding lipid, protein and carbohydrate technology platforms

  7. Slide 7: Martek Today

    Martek Today The global leader in DHA and ARA for infant formula Growing DHA business outside of infant formula Recently acquired platform from which to launch branded nutritional products Strong balance sheet and cash flow generation Annual revenue more than $450 million (post-Amerifit acquisition)

  8. Slide 8: Martek's "Go Forward" Strategy

    Martek’s “Go Forward” Strategy 8 Leverage microbial biotechnology platform to expand beyond DHA and ARA Internally commercialize nutritionally-oriented pipeline products Seek strong industry partners for pipeline products outside of nutrition Continue to leverage our platform to deliver shareholder

  9. Slide 9: Peter Nitze, Chief Operating Officer

    Peter Nitze Chief Operating Officer 9

  10. Slide 10: Martek Research Engine

    Martek Research Engine 10 Nutritional Ingredients Commercial Applications Branded Nutritional Supplements (Amerifit) Unique Microbial Production Systems Comprehensive lab, pilot and production scale manufacturing Microbial biology Algal genomics Fermentation and oil processing Proprietary Platform C

  11. Slide 11: Martek Research and Development Capabilities

    11 108 R&D team members (42 Ph.D.s, 2 M.D.s) Prior affiliations include National Institutes of Health, Abbott, Johnson & Johnson, Wyeth, Monsanto Experience with algae, bacteria, fungi, yeast and other microbes Expertise in modification, optimization, development and production of microbes and micro

  12. Slide 12: Project Pipeline Overview

    Project Pipeline Overview Project Description Partner Therapeutic Proteins Algal-based protein expression platform Confidential Microbial Biofuels Conversion of sugar into biodiesel through fermentation Seed Oil DHA Oilseed-based production system for DHA High Purity DHA 90+% pure DHA product for th

  13. Slide 13: MIDAS Overview

    MIDAS Overview Overview A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DHA on Cognitive Functions in Healthy Elderly Adults Commercial Application Branded nutritional supplement Compelling Attributes Benefit roughly equivalent to having the learning and memory skills

  14. Slide 14: Microbial EPA/DHA Overview

    Microbial EPA/DHA Overview Martek has developed a new strain of algae with a fatty acid profile that is similar to higher quality fish oils Commercial Application(s) Branded nutritional supplement Food & beverage ingredient Compelling Attributes Non-GMO A vegetarian, sustainable EPA + DHA alternativ

  15. Slide 15: Next Generation DHA for Infant Formula

    Next Generation DHA for Infant Formula 15 Overview A new strain of algae with similar fatty acid profile to the current DHA for infant formula Commercial Application Infant formula Compelling Attributes Non-GMO More rapid and efficient growth than current IF algal strain Timing Targeted commercializ

  16. Slide 16: Therapeutic Protein Production System

    Therapeutic Protein Production System 16 Overview A novel production system for therapeutic proteins Proof of concept achieved Positive results demonstrated in animal vaccine challenge trial Commercial Application(s) Algal-based protein expression platform for therapeutically important proteins Mart

  17. Slide 17: Protein Production System Comparisons

    System Vaccine Development Protein Secretion Cost / Cycle Time Capacity Risks Bacteria Fast (weeks) No Low / Fast High Impurities Yeast Fast (weeks) Yes Medium / Fast High HM Issues* Plants Very Slow (many months) Varies Low / Slow Very High Containment Animals Very Slow (many months) Yes High / Slo

  18. Slide 18: Chondroitin Overview

    Chondroitin 18 Overview Chondroitin sulfate is a carbohydrate polymer found in all joints Chondroitin is currently produced from animal sources such as bovine, porcine, and shark cartilage Martek is commercializing a consistent, dependable low-cost form of chondroitin sulfate through bacterial ferme

  19. Slide 19: BP/Martek Sugar to Diesel Project overview

    BP/Martek Sugar to Diesel Project overview Philip New, CEO BP Biofuels Martek Investor Day, New York, 5th March 2010 BP Biofuels a growing alternative

  20. Slide 20: Forward Looking Statements

    21 Forward Looking Statements This presentation contains forward-looking statements based on management’s current expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the company’s strategy for growth, product d

  21. Slide 21: BP Biofuels Strategy

    22 BP Biofuels Strategy Bioethanol Biobutanol Sugar Fermentation Grain Energy Crop Sugar cane Sustainable Feedstock Conversion Fuel Molecules Gasoline Biodiesel Diesel A sustainable & scalable option to meet increasing demand for biodiesel Power/Feed

  22. Slide 22: About BP Biofuels

    23 About BP Biofuels Continually improving how biofuels are sourced, developed, and consumed through the thoughtful application of advanced technologies and operations, Projects in Construction Brazilian JV Tropical BioEnergia SA operating a wordscale sugarcane ethanol plant UK Joint Venture constru

  23. Slide 23: BP / Martek Sugar to Diesel Collaboration

    24 BP / Martek Sugar to Diesel Collaboration A summary Technology offers an alternative to current biodiesel options with potential to deliver economic, sustainable and scaleable biodiesel supplies: Access to a variety of biomass feedstock Ability to tailor the product to specific applications Reduc

  24. Slide 24: BP-Martek Sugar to Diesel Technology

    25 BP-Martek Sugar to Diesel Technology Steps: Access cost effective and sustainable sugar juice extracted from sugar cane or Ligno-cellulosic material Use proprietary heterotrophic micro- organism to convert the sugars into lipids / oils. Lipids produced have profiles and/or properties similar to c

  25. Slide 25: Photosynthetic versus Heterotrophic

    26 Photosynthetic versus Heterotrophic Low cost / Low-carbon / Scalable / Sustainable Four criteria against which we judge opportunities: Open Pond Photoreactors Heterotrophic Photosynthetic Sun, Water, CO2 Conversion Oil Conventional Fermenters Oil in microorganism Process Control Productivity Prod

  26. Slide 26: Market Opportunity

    27 Market Opportunity Advantages of the sugar-to-diesel pathway over conventional biodiesel made from vegetable oils include: Access to a wide variety of biomass feedstocks which can be produced at scale and in high yield. Ability to tailor the product for a variety of diesel and aviation-fuel needs

  27. Slide 27: Market Opportunity

    28 Market Opportunity Sugar to Diesel (S2D) is a low cost, low carbon, scalable option with large potential to access key high growth biofuels markets in the short term ... ... and a long term response to the evolution of the road transport fuel sector and Aviation. Regulation driven market growth a

  28. Slide 28: Question & Answer Session

    Question & Answer Session 29

  29. Slide 29: David Abramson, President

    David Abramson President 30

  30. Slide 30: Amerifit Overview

    Amerifit Overview Develops, markets and distributes branded consumer health and wellness products focused on Women’s and Digestive Health benefits Product portfolio of leading brands: Culterelle, AZO and Estroven Broad U.S. distribution throughout food, drug, and mass channels 31

  31. Slide 31: Strategic Value of Amerifit

    Strategic Value of Amerifit Strong sales and marketing infrastructure for selling branded consumer health and wellness products Moves Martek up the value chain and closer to the consumer Platform for controlling and accelerating the commercialization of Martek’s nutritional product pipeline 32 Brand

  32. Slide 32: Leveraging the MIDAS Study

    Leveraging the MIDAS Study Publication by a major medical journal Stage is set for a branded “life’sDHA for memory” product Large and growing market opportunity (Baby Boomers) PR campaign 33 Journal Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore

  33. Slide 33: Branded Product Pipeline Opportunities

    Branded Product Pipeline Opportunities DHA for Memory (MIDAS) Other product concepts * Chondroitin 2010 2011 2012 2013 Amerifit Products Martek Product Concepts Culterelle Estroven AZO DHA-combination concepts * Cardiovascular * Cognitive * Joint * Bone * Children’s On the Market Development Vegetar

  34. Slide 34: Peter Buzy, Chief Financial Officer

    Peter Buzy Chief Financial Officer 35

  35. Slide 35: Finance Summary

    Finance Summary 36 Core research capabilities have been developed over many years Most individual products have a 3-5 year development cycle Strategic partnerships leverage our development spending m m

  36. Slide 36: Disciplined Spending

    Disciplined Spending Rigorous screening process 37 Partnership Opportunity Time to Market Intellectual Property Technical Feasibility Revenue Potential Martek Projects

  37. Slide 37: Steve Dubin, Chief Executive Officer

    Steve Dubin Chief Executive Officer 38

  38. Slide 38: Today's Takeaways

    Today’s Takeaways 39 Strong technology platform Robust pipeline of near and long-term products Capabilities to execute and commercialize the pipeline Branded nutritional products - Amerifit High value products - growing list of strategic partnerships with marquee partners Continued focus on revenue

  39. Slide 39: Question & Answer Session

    Question & Answer Session 40

Martek Biosciences — Investor Day (March 2010) on 6ix